183 related articles for article (PubMed ID: 22271478)
1. Deep time: the long and the short of adjuvant endocrine therapy for breast cancer.
Burstein HJ; Griggs JJ
J Clin Oncol; 2012 Mar; 30(7):684-6. PubMed ID: 22271478
[No Abstract] [Full Text] [Related]
2. Overview of adjuvant trials of aromatase inhibitors in early breast cancer.
Ingle JN
Steroids; 2011 Jul; 76(8):765-7. PubMed ID: 21382394
[TBL] [Abstract][Full Text] [Related]
3. Current developments in hormonal therapy of breast cancer.
Buzdar AU
Clin Breast Cancer; 2004 Sep; 5 Suppl 1():S4-5. PubMed ID: 15347432
[No Abstract] [Full Text] [Related]
4. [Antiestrogen treatment in postmenopausal patients with metastatic breast cancer].
Lindberg H; Nielsen DL; Tuxen M; Kamby C
Ugeskr Laeger; 2007 Sep; 169(37):3096-100. PubMed ID: 17877958
[TBL] [Abstract][Full Text] [Related]
5. Recent advances in aromatase inhibitor therapy for breast cancer.
Assikis VJ; Buzdar A
Semin Oncol; 2002 Jun; 29(3 Suppl 11):120-8. PubMed ID: 12138406
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant aromatase inhibitor therapy for early breast cancer: A review of the most recent data.
Grana G
J Surg Oncol; 2006 Jun; 93(7):585-92. PubMed ID: 16705732
[TBL] [Abstract][Full Text] [Related]
7. Aromatase inhibitors for the endocrine adjuvant treatment of breast cancer.
Ravdin P
Lancet; 2002 Jun; 359(9324):2126-7. PubMed ID: 12090973
[No Abstract] [Full Text] [Related]
8. Controversies in endocrine treatment: effective utilization of steroidal and nonsteroidal aromatase inhibitors: now and in the future. Forward.
Aapro M
Anticancer Drugs; 2008 Mar; 19 Suppl 2():S1. PubMed ID: 18337639
[No Abstract] [Full Text] [Related]
9. [Advancement in endocrine therapy for breast cancer].
Yang MT; Lian ZQ
Ai Zheng; 2007 Apr; 26(4):440-4. PubMed ID: 17430670
[TBL] [Abstract][Full Text] [Related]
10. Current role of endocrine therapy in the management of breast cancer.
Robertson JF
Breast Cancer; 2002; 9(4):276-81. PubMed ID: 12459706
[No Abstract] [Full Text] [Related]
11. Aromatase inhibitors and inactivators in breast cancer.
Lønning PE
BMJ; 2001 Oct; 323(7318):880-1. PubMed ID: 11668120
[No Abstract] [Full Text] [Related]
12. Letrozole compared with tamoxifen as initial adjuvant therapy for breast cancer.
Buzdar AU
J Clin Oncol; 2007 May; 25(15):2147-8; author reply 2148. PubMed ID: 17513830
[No Abstract] [Full Text] [Related]
13. Nonsteroidal and steroidal aromatase inhibitors in breast cancer.
Hamilton A; Volm M
Oncology (Williston Park); 2001 Aug; 15(8):965-72; discussion 972, 977-9. PubMed ID: 11548977
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant aromatase inhibitors for breast cancer.
Howell A
Lancet; 2005 Aug 6-12; 366(9484):431-3. PubMed ID: 16084234
[No Abstract] [Full Text] [Related]
15. Using aromatase inhibitors in the neoadjuvant setting: evolution or revolution?
Freedman OC; Verma S; Clemons MJ
Cancer Treat Rev; 2005 Feb; 31(1):1-17. PubMed ID: 15707700
[TBL] [Abstract][Full Text] [Related]
16. Benefit with aromatase inhibitors in the adjuvant setting for postmenopausal women with breast cancer.
Mouridsen HT; Robert NJ
MedGenMed; 2005 Aug; 7(3):20. PubMed ID: 16369246
[TBL] [Abstract][Full Text] [Related]
17. The impact of adjuvant endocrine therapy on reducing the risk of distant metastases in hormone-responsive breast cancer.
Herold CI; Blackwell KL
Breast; 2008 Jan; 17 Suppl 1():S15-24. PubMed ID: 18279763
[TBL] [Abstract][Full Text] [Related]
18. Unravelling exemestane: From biology to clinical prospects.
Sobral AF; Amaral C; Correia-da-Silva G; Teixeira N
J Steroid Biochem Mol Biol; 2016 Oct; 163():1-11. PubMed ID: 26992705
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant ovarian suppression in premenopausal breast cancer.
Montemurro F; Perrone F; Geuna E
N Engl J Med; 2015 Apr; 372(17):1672-3. PubMed ID: 25901438
[No Abstract] [Full Text] [Related]
20. Adjuvant ovarian suppression in premenopausal breast cancer.
Francis PA; Regan MM; Fleming GF
N Engl J Med; 2015 Apr; 372(17):1673. PubMed ID: 25901437
[No Abstract] [Full Text] [Related]
[Next] [New Search]
